Arcturus Therapeutics, a biotech company valued at $194.3 million, has seen its stock rise by 10% this year. The company is known for developing mRNA-based medicines and vaccines, including the world’s first approved self-amplifying mRNA Covid-19 vaccine. Arcturus is also working on mRNA therapies for cystic fibrosis and ornithine transcarbamylase deficiency.

Arcturus is gaining attention as a high-risk, high-reward biotech stock due to positive clinical data for its cystic fibrosis treatment. The company is planning further studies for its CF and OTC deficiency programs, with revenue coming from licensing and collaboration fees. Wall Street rates ARCT stock a “Moderate Buy,” with analysts predicting a potential 404% rally in stock price.

Read more at Barchart: 1 Under-$10 Stock Set to Surge as Much as 963% in 2026